2-Chloro-N-(2,2-diphenylethyl)-adenosine 2',3',5'-triacetate | 98383-72-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-Chloro-N-(2,2-diphenylethyl)-adenosine 2',3',5'-triacetate
• 英文别名: [(2R,3R,4R,5R)-3,4-diacetyloxy-5-[2-chloro-6-(2,2-diphenylethylamino)purin-9-yl]oxolan-2-yl]methyl acetate
• CAS: 98383-72-3
• 化学式: C₃₀H₃₀ClN₅O₇
• 分子量: 608.051
• InChiKey: QOURLNLGJMAFDA-CTDWIVFPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  43
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  144
• 氢给体数：
  1
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-Chloro-N-(2,2-diphenylethyl)-adenosine 2',3',5'-triacetate 在 氢氧化钾 、 potassium permanganate 、 氯化亚砜 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 丙酮 为溶剂， 生成 (3aS,4S,6R,6aR)-6-[2-Chloro-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carbonyl chloride
  参考文献：
  名称：

  The discovery and synthesis of highly potent, A 2a receptor agonists

  摘要：

  A series of N6,2-disubstituted adenosine analogues have been synthesized and their functional activity measured against A(2a) and A(1) receptors. Examples of compounds with both a lipophilic N6-substituent and amino-functionalized 2-position were highly active at the A(2a) receptor on the human neutrophil. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00017-2
• 作为产物：
  描述：

  2',3',5'-三乙酰鸟苷 在 亚硝酸特丁酯 、 四乙基氯化铵 、 吡啶盐酸盐 、 N,N-二甲基苯胺 、 N,N-二异丙基乙胺 、 copper(l) chloride 、 三氯氧磷 作用下， 以 二氯甲烷 、 异丙醇 、 乙腈 为溶剂， 生成 2-Chloro-N-(2,2-diphenylethyl)-adenosine 2',3',5'-triacetate
  参考文献：
  名称：

  The discovery and synthesis of highly potent, A 2a receptor agonists

  摘要：

  A series of N6,2-disubstituted adenosine analogues have been synthesized and their functional activity measured against A(2a) and A(1) receptors. Examples of compounds with both a lipophilic N6-substituent and amino-functionalized 2-position were highly active at the A(2a) receptor on the human neutrophil. (C) 2000 Published by Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(00)00017-2

文献信息

• 2-6-diaminopurine precursors
  申请人：Glaxo Group Limited

  公开号：US05889178A1

  公开（公告）日：1999-03-30

  The present invention relates to compounds of formula (IV): ##STR1## wherein R.sup.a and R.sup.b each represent a hydrogen atom or together form an alkylidene group.

  本发明涉及化合物的公式(IV)：##STR1##其中R.sup.a和R.sup.b分别代表氢原子或共同形成一个烷基亚烯基团。
• A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity
  作者：Andrea Spinaci、Michela Buccioni、Diego Dal Ben、Federica Maggi、Gabriella Marucci、Beatrice Francucci、Giorgio Santoni、Catia Lambertucci、Rosaria Volpini

  DOI：10.3390/ph15020164

  日期：——

  more pronounced effects with respect to the ones elicited by the reference full agonist Cl-IB-MECA. In particular, the N6-(2,2-diphenylethyl)-2-phenylethynylAdo (12: GI50 = 14 µM, TGI = 29 µM, and LC50 = 59 µM) showed the highest activity proving to be a potential antitumor agent. The cytostatic effect of both A3AR agonist (Cl-IB-MECA) and antagonists (12 and other newly synthesized compounds) confirm

  A3 腺苷受体 (AR) 在多种癌细胞类型中的过表达使其成为肿瘤诊断和治疗的有吸引力的靶标。因此，在寻找新的 A3AR 配体时，合成了一系列新的 2,N6-二取代腺苷 (Ados)，并在 AR 的放射性配体结合和功能测定中进行了测试。发现在 N6 位带有 2-苯乙氨基的衍生物比相应的 N6-(2,2-二苯乙基) 类似物具有更高的 A3AR 亲和力和选择性。在 cAMP 积累试验中，发现 2-Chloro-N6-phenylethylAdo (15) 是一种有效的全 A3AR 激动剂，Ki 为 0.024 nM，EC50 为 14 nM。与 15 不同，其他配体表现为 A3AR 拮抗剂，其浓度依赖性地降低细胞生长并对前列腺癌细胞系 PC3 发挥细胞抑制活性，显示出与参考完全激动剂 Cl-IB-MECA 引发的效果相当甚至更显着的效果。特别是 N6-(2,2-diphenylethyl)-2-phenylethynylAdo
• [EN] 2,6-DIAMINOPURINE DERIVATIVES<br/>[FR] DERIVES DE LA 2,6-DIAMINOPURINE
  申请人：GLAXO GROUP LIMITED

  公开号：WO1994017090A1

  公开（公告）日：1994-08-04

  (EN) 2,6-Diaminopurine-$g(b)-D-ribofuranuronamide derivatives are described having general formula (I) and salts and solvates thereof, wherein: R1 is hydrogen, C3-8cycloalkyl or C1-6alkyl; R2 is C3-8cycloalkyl, C3-8cycloalkylC1-6alkyl, Alk1Y, -(CHR5)m(Alk2)nZ or appropriately substituted C3-8cycloalkyl, C3-8cycloalkylC1-6alkyl, pyrrolidin-3-yl, 2-oxopyrrolidin-4-yl, 2-oxopyrrolidin-5-yl, piperidin-3-yl or piperidin-4-yl, and Q is oxygen or sulphur. Compounds of formula (I) and their salts and solvates have use in medicine as anti-inflammatory agents, particularly in the treatment of patients with inflammatory conditions who are susceptible to leukocyte-induced tissue damage.(FR) On décrit des dérivés du 2,6-diaminopurine-$g(b)-D-ribofuranuronamide ayant la formule générale (I) ainsi que leurs sels et solvates. Dans cette formule: R1 est un hydrogène, un C3-8cycloalkyle ou un C1-6alkyle; R2 est un C3-8cycloalkyle, un C3-8cycloalkylC1-6alkyle, un Alk1Y, un -(CHR5)m(Alk2)nZ ou un des groupes suivants, portant des substituants appropriés: C3-8cycloalkyle, C3-8cycloalkylC1-6alkyle, pyrrolidin-3-yle, 2-oxopyrrolidin-4-yle, 2-oxopyrrolidin-5-yle, pipéridin-3-yle ou pipéridin-4-yle, et Q est oxygène ou le soufre. Les composés de la formule (I) et leurs sels et solvates sont utiles en médecine comme agents anti-inflammatoires, en particulier pour le traitement de patients souffrant d'affections inflammatoires avec risques de lésions tissulaires, induites par les leucocytes.

  描述了具有通式(I)及其盐和溶剂化物的2,6-二氨基嘌呤-$g(b)-D-核糖尿苷衍生物，其中：R1为氢、C3-8环烷基或C1-6烷基；R2为C3-8环烷基、C3-8环烷基C1-6烷基、Alk1Y、-(CHR5)m(Alk2)nZ或适当取代的C3-8环烷基、C3-8环烷基C1-6烷基、吡咯烷-3-基、2-氧代吡咯烷-4-基、2-氧代吡咯烷-5-基、哌啶-3-基或哌啶-4-基，Q为氧或硫。通式(I)化合物及其盐和溶剂化物在医学上具有抗炎作用，特别是用于治疗易受白细胞诱导的组织损伤的炎症病患。
• 2,6-Di (substitutedamino) purine ribonucleoside analogues and
  申请人：Glaxo Group Limited

  公开号：US05925624A1

  公开（公告）日：1999-07-20

  The present invention relates to 2,6-diaminopurine-.beta.-D-ribofuranuronamide derivatives of the following formula (I). These compounds and their salts and solvates are useful as anti-inflammatory agents, particularly in the treatment of patients with inflammatory conditions who are susceptible to leukocyte-induced tissue damage. ##STR1##

  本发明涉及以下式(I)的2,6-二氨基嘌呤-.beta.-D-核糖醛酰脲衍生物。这些化合物及其盐和溶剂化物可用作抗炎剂，特别是用于治疗易受白细胞引起的组织损伤的炎症病患者。
• N6-substituted diarylalkyl adenosines, processes for their production and pharmaceutical compositions comprising the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0139358A2

  公开（公告）日：1985-05-02

  N6 -Substittuted diarylalkyladenosines of the formula: are disclosed. Processes for their manufacture and pharmaceutical compositions containing the same are also disclosed. The compounds have highly desirable central- nervous system and cardio-vascular properties.

  式中的 N6-取代二芳基烷基腺苷： 的二芳基烷基腺苷。还公开了其制造工艺和含有这些化合物的药物组合物。这些化合物具有非常理想的中枢神经系统和心血管特性。